Stockreport

Merck: Why Investors Should Remain Bullish Despite Patent Risks [Seeking Alpha]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF One of the key reasons Merck is once again becoming a Wall Street favorite is the 6.8% year-over-year increase in sales of pembrolizumab franchise to $8.37 billion in Q [Read more]